Adam Lee

1.0k total citations · 1 hit paper
32 papers, 359 citations indexed

About

Adam Lee is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Infectious Diseases. According to data from OpenAlex, Adam Lee has authored 32 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 5 papers in Infectious Diseases. Recurrent topics in Adam Lee's work include Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Colorectal Cancer Treatments and Studies (4 papers). Adam Lee is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Colorectal Cancer Treatments and Studies (4 papers). Adam Lee collaborates with scholars based in United States, United Kingdom and Germany. Adam Lee's co-authors include Adi V. Gundlapalli, Adam MacNeil, Kristie E.N. Clarke, Yangyang Deng, Ronaldo Iachan, Aron J. Hall, Jefferson M. Jones, Robert B. Diasio, Jeanne Fourie and Hany Ezzeldin and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Adam Lee

26 papers receiving 343 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022

2022 164 citations Kristie E.N. Clarke, Jefferson M. Jones et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adam Lee United States	8	157	92	85	36	33	32	359
Anwar A. Sayed Saudi Arabia	9	79 0.5×	66 0.7×	34 0.4×	19 0.5×	39 1.2×	34	277
Héctor Alexander Velásquez García Canada	11	137 0.9×	60 0.7×	20 0.2×	26 0.7×	33 1.0×	43	325
Ibrahim Alghamdi Saudi Arabia	8	108 0.7×	119 1.3×	19 0.2×	31 0.9×	12 0.4×	17	328
Gordon Hay United Kingdom	12	170 1.1×	100 1.1×	23 0.3×	27 0.8×	10 0.3×	30	524
Xingguang Lin China	12	131 0.8×	164 1.8×	43 0.5×	12 0.3×	19 0.6×	27	971
Shengxia Yin China	11	197 1.3×	43 0.5×	45 0.5×	44 1.2×	18 0.5×	36	464
Om Prakash India	11	107 0.7×	145 1.6×	43 0.5×	35 1.0×	13 0.4×	42	468
Xiucui Han China	8	137 0.9×	35 0.4×	23 0.3×	10 0.3×	32 1.0×	13	287
Philippos Edimiris Germany	7	84 0.5×	193 2.1×	30 0.4×	18 0.5×	6 0.2×	19	494
Hajar Abbasi Iran	10	84 0.5×	78 0.8×	36 0.4×	9 0.3×	7 0.2×	21	492

Countries citing papers authored by Adam Lee

Since Specialization

Citations

This map shows the geographic impact of Adam Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Lee more than expected).

Fields of papers citing papers by Adam Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Lee. The network helps show where Adam Lee may publish in the future.

Co-authorship network of co-authors of Adam Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Lee. A scholar is included among the top collaborators of Adam Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Lee. Adam Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Chouaïd, C., D. Debieuvre, Clarisse Audigier-Valette, et al.. (2025). Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis. Frontiers in Oncology. 15. 1526931–1526931. 1 indexed citations

2.

Peters, Solange, Meredith M. Regan, Luis Paz‐Ares, et al.. (2025). Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1. Journal of Thoracic Oncology. 20(10). 1505–1516.

3.

Wolf, Jürgen, Sarah Goring, Adam Lee, et al.. (2025). Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC. Cancers. 17(5). 748–748.

4.

Reck, Martin, Luis Paz‐Ares, Yong Yuan, et al.. (2024). Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer. Clinical Lung Cancer. 25(7). e362–e368.

5.

Griffiths, Alison, et al.. (2024). Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year Data. PharmacoEconomics - Open. 9(2). 247–257.

6.

Lee, Adam, et al.. (2023). Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey. BMC Cancer. 23(1). 603–603. 7 indexed citations

7.

Lee, Adam, Lu Liang, Phillippa L. Connerton, Ian F. Connerton, & Kenneth H. Mellits. (2023). Galacto-oligosaccharides fed during gestation increase Rotavirus A specific antibodies in sow colostrum, modulate the microbiome, and reduce infectivity in neonatal piglets in a commercial farm setting. Frontiers in Veterinary Science. 10. 1118302–1118302. 5 indexed citations

8.

Lee, Adam, et al.. (2022). COVID-19 data driven planning: The SouthEast Texas approach. Journal of Emergency Management. 20(7). 39–56.

9.

Wiegand, Ryan E., Yangyang Deng, Adam Lee, et al.. (2022). Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States—October 25, 2020–February 26, 2022. The Lancet Regional Health - Americas. 18. 100403–100403. 29 indexed citations

10.

Chaudhary, Mohammad A., Yong Yuan, N. Varol, et al.. (2022). Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States. Journal of Medical Economics. 25(1). 703–711. 5 indexed citations

11.

Lee, Adam, et al.. (2022). Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies. Cancer Treatment and Research Communications. 33. 100648–100648. 5 indexed citations

12.

Goring, Sarah, N. Varol, Nathalie Waser, et al.. (2022). Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis. Lung Cancer. 170. 122–132. 7 indexed citations

13.

Twelves, Chris, Sue Cheeseman, Will Sopwith, et al.. (2020). Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre. BMC Cancer. 20(1). 53–53. 11 indexed citations

14.

Johnson, Christopher H., Linda Beer, Ronaldo Iachan, et al.. (2020). Changes to the sample design and weighting methods of a public health surveillance system to also include persons not receiving HIV medical care. PLoS ONE. 15(12). e0243351–e0243351. 4 indexed citations

15.

Suri, Gaurav, David Chandiwana, Adam Lee, & Rohit Mistry. (2019). Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom. Journal of health economics and outcomes research. 20–31. 1 indexed citations

16.

Suri, Gaurav, David Chandiwana, Adam Lee, & Rohit Mistry. (2019). Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom. Journal of health economics and outcomes research. 6(2). 20–31. 12 indexed citations

17.

Lee, Adam, et al.. (2016). Juvenile Polyposis coli in a 9 year old boy. 7(1). 47–51. 1 indexed citations

18.

Binder, Moritz, et al.. (2016). Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences. 17(7). 1097–1097. 19 indexed citations

19.

Ezzeldin, Hany, Lori K. Mattison, Holly R. Thomas, et al.. (2007). Genotypic characterization of dihydropyrimidinase andβ-ureidopropionase in an African American and Caucasian population: New potential pharmacogenetic markers for 5-fluorouracil toxicity in the African American population. Cancer Epidemiology and Prevention Biomarkers. 16. 1 indexed citations

20.

Liesveld, Jane L., et al.. (2007). Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients. Cancer Genetics and Cytogenetics. 174(2). 132–137. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact